Text Size

Cost-Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany

Lazzaro, C.; van Steen, C.; Billeit, S.; Frauenknecht, H.; Kallen, C.; Pfennigsdorf, S.; Thelen, U.; Angelillo, L.


  • 2022
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Affiliations

    Health Economist and Research Director, Studio di Economia Sanitaria, Milan, Italy; Santen GmbH, München, Germany; Private Practicing Ophthalmologist, Lübeck, Germany; Private Practicing Ophthalmologist, Treuchtlingen, Germany; Private Practicing Ophthalmologist, Krefeld, Germany; Private Practicing Ophthalmologist, Polch, Germany; Private Practicing Ophthalmologist, Münster, Germany; University Hospital Muenster, Department of Ophthalmology, Münster, Germany

Related Publications

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF


Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.


Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022